Kenneth J. Hillan

CIK 1600359 · Chief Therapeutics Officer · last filed 2025-06-16

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

5

Total Filings

35

Lifetime Open-Market Net

-$295.8K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SANGAMO THERAPEUTICS, INC (SGMO) Delisted Director 99,600 $0.18 $17.7K $0 6 2025-06-16
ZYME Director $22.88 $0 5 2023-12-08
Chrome Holding Co. (ME) Delisted Chief Therapeutics Officer 237,223 $0.61 $143.8K -$31.9K 8 2023-06-07
Achaogen, Inc. (AKAO) Delisted See Remarks 293,336 -$244.3K 12 2018-06-29
Relypsa Inc (RLYP) Delisted Director 2,250 -$19.6K 4 2016-09-02

Recent Filings · Page 4 of 4

35 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2016-06-08 Relypsa Inc (RLYP) Delisted Sell (S) −1,013 -$19.6K EDGAR
2016-03-21 Achaogen, Inc. (AKAO) Delisted Sell (S) −3,572 -$11.5K EDGAR
2016-03-01 Achaogen, Inc. (AKAO) Delisted Grant (A) +33,000 $0 EDGAR
2015-06-08 Relypsa Inc (RLYP) Delisted Grant (A) +2,250 $0 EDGAR
2015-03-13 Achaogen, Inc. (AKAO) Delisted Grant (A) +32,200 $0 EDGAR
Showing 3135 of 35
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.